129 results match your criteria: "St Jude Medical Center.[Affiliation]"
Br J Sports Med
February 2015
Department of Physical Medicine and Rehabilitation, Mayo Clinic College of Medicine, Mayo Clinic Sports Medicine Center, Rochester, Minnesota, USA Department of Radiology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Background: The use of diagnostic and interventional ultrasound has significantly increased over the past decade. A majority of the increased utilisation is by non-radiologists. In sports medicine, ultrasound is often used to guide interventions such as aspirations, diagnostic or therapeutic injections, tenotomies, releases and hydrodissections.
View Article and Find Full Text PDFArch Pathol Lab Med
June 2015
Department of Pathology, St Jude Medical Center, Fullerton, CA 92835.
Arch Pathol Lab Med
May 2015
From the Department of Pathology, St Joseph Mercy Hospital, Ann Arbor, Michigan (Dr Bartley); Cancer Registry, Sanford Health Medical Center, Fargo, North Dakota (Ms Christ); the Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston (Dr Hamilton); the Department of Pathology, University of California, San Francisco, and the Veterans Affairs Medical Center, San Francisco, California (Dr Kakar); the Department of Pathology, Weill Cornell Medical College, New York, New York (Dr Shah); the Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York (Dr Tang); and the Department of Pathology, Oregon Health and Science University, Portland (Dr Troxell).
Arch Pathol Lab Med
May 2015
From the Department of Pathology, Park Nicollet-Methodist Hospital, St Louis Park, Minnesota (Dr Simpson); the Department of Pathology, Jefferson Regional Medical Center, Jefferson Hills, Pennsylvania (Dr Berman); the University of South Florida Department of Pathology and Cell Biology, James A. Haley Veterans' Hospital, Tampa (Dr Foulis); the Department of Laboratory Medicine, Grand River Hospital, Kitchener, Ontario, Canada (Dr Divaris); the Department of Pathology, Grady Health System/Emory University School of Medicine, Atlanta, Georgia (Dr Birdsong); Capability & Specialty Advancement, College of American Pathologists, Northfield, Illinois (Drs Mirza, Moldwin, and Spencer); the Laboratory Medicine and Genetics Program, Trillium Health Partners, Mississauga, Ontario, Canada (Dr Srigley); and the Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons).
Context: The College of American Pathologists has been producing cancer protocols since 1986 to aid pathologists in the diagnosis and reporting of cancer cases. Many pathologists use the included cancer case summaries as templates for dictation/data entry into the final pathology report. These summaries are now available in a computer-readable format with structured data elements for interoperability, packaged as "electronic cancer checklists.
View Article and Find Full Text PDFArch Pathol Lab Med
July 2014
From the Department of Anatomic Pathology, Cleveland Clinic foundation, Cleveland, Ohio (Dr Dyhdalo); the Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts (Dr Goldsmith); the Department of Biostatistics, College of American Pathologists, Northfield, Illinois (Ms Souers); and the Department of Pathology, Mayo Clinic Florida, Jacksonville (Dr Nakhleh).
Context: The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) published guidelines in 2007 regarding testing accuracy, interpretation, and reporting of results for HER2 studies. A 2008 survey identified areas needing improved compliance.
Objective: To reassess laboratory response to those guidelines following a full accreditation cycle for an updated snapshot of laboratory practices regarding ASCO/CAP guidelines.
Arch Pathol Lab Med
July 2014
From the Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons); and the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York (Dr Hicks).
Neurocrit Care
October 2014
St. Jude Medical Center, Fullerton, CA, USA,
Arch Pathol Lab Med
November 2014
From the Department of Pathology, St. Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the Department of Pathology and Laboratory Medicine, Women & Infants Hospital/Brown University, Providence, Rhode Island (Dr Bradley); the College of American Pathologists, Northfield, Illinois (Ms Fatheree and Mr Smith); the Department of Pathology, Kaiser Permanente - Los Angeles Medical Center, Los Angeles, California (Dr Alsabeh); PhenoPath Laboratories, Seattle, Washington (Dr Fulton); the Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts (Dr Goldsmith); the Department of Pathology, Mercy Hospital, Janesville, Wisconsin (Dr Haas); the Department of Pathology, Montefiore Medical Center, New York, New York (Dr Karabakhtsian); Regional Medical Laboratory, St John's Medical Center, Tulsa, Oklahoma (Ms Loykasek); the Department of Pathology, University of Minnesota Medical Center, Fairview, Minneapolis (Dr Marolt); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Shen); and the Department of Pathology, University of Washington Medical Center, Seattle (Dr Swanson).
Context: Laboratories must validate all assays before they can be used to test patient specimens, but currently there are no evidence-based guidelines regarding validation of immunohistochemical assays.
Objective: To develop recommendations for initial analytic validation and revalidation of immunohistochemical assays.
Design: The College of American Pathologists Pathology and Laboratory Quality Center convened a panel of pathologists and histotechnologists with expertise in immunohistochemistry to develop validation recommendations.
Ment Health Phys Act
October 2013
Il Do Taekwondo, Irvine, California.
There is growing consensus that exercise improves cognitive functioning, but research is needed to identify exercise interventions that optimize effects on cognition. The objective of this pilot study was to evaluate Taekwondo implemented in public middle school physical education (PE). Two classes were randomly assigned to either: five sessions per week of PE or three sessions of PE and two sessions of Taekwondo.
View Article and Find Full Text PDFArch Pathol Lab Med
May 2014
From the Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dr Dillon); the Department of Pathology, Kaiser Permanente-Los Angeles Medical Center, Los Angeles, California (Dr Alsabeh); the Department of Pathology, Jefferson Hospital, Jefferson Hills, Pennsylvania (Dr Berman); the Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor (Dr Hayes); the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York (Dr Hicks); the Division of Surgical Oncology, Massachusetts General Hospital, Boston (Dr Hughes); and the Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (Dr Nofech-Mozes).
J Clin Oncol
November 2013
Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI.
Purpose: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer.
Methods: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing.
Results: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH).
Arch Pathol Lab Med
February 2014
Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI.
Purpose: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer.
Methods: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing.
Results: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH).
Arch Pathol Lab Med
April 2014
From the Department of Pathology, University of North Carolina, Chapel Hill (Dr Gulley); the Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the College of American Pathologists, Northfield, Illinois (Ms Kennedy); the Department of Translational Medicine, Biogen Idec, Cambridge, Massachusetts (Dr Cosentino); the Department of Pathology, Vanderbilt Medical Center, Nashville, Tennessee (Dr Washington); the Department of Pathology, Duke Medical Center, Durham, North Carolina (Dr Dash); the Biorepositories and Biospecimens Research Branch, National Cancer Institute, National Institutes of Health, Rockville, Maryland (Dr Branton); the Department of Biospecimen Science, Van Andel Institute, Grand Rapids, Michigan (Dr Jewell); and the Department of Pathology, Spartanburg Regional Medical Center, Spartanburg, South Carolina (Dr Lapham).
Context: Biospecimens must have appropriate clinical annotation (data) to ensure optimal quality for both patient care and research. Clinical preanalytic variables are the focus of this study.
Objective: To define the essential preanalytic variables (data fields) that should be attached to every collected biospecimen and to provide a complete list of such variables, along with their relative importance, which can vary, depending on downstream use, institutional needs, and information technology capabilities.
Arch Pathol Lab Med
February 2014
From the Department of Pathology, St Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston (Dr Lazar); and the College of American Pathologists, Northfield, Illinois (Dr Spencer).
Arch Pathol Lab Med
February 2014
From the Department of Pathology, St. Joseph Mercy Hospital, Ann Arbor, Michigan (Dr Bartley); the Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston (Dr Hamilton); the Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York (Dr Ambinder); the Department of Pathology, Jefferson Regional Medical Center, Jefferson Hills, Pennsylvania (Dr Berman); St Paul, Minnesota (Ms Collins); the Department of Pathology, St. Jude Medical Center, Fullerton, California (Dr Fitzgibbons); the American Joint Committee on Cancer, Chicago, Illinois (Ms Gress); the Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, Illinois (Dr Nowak); the Department of Pathology, University of Utah, Salt Lake City (Dr Samowitz); and the Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina (Dr Zafar). Dr Alsabeh is in private practice, Beverly Hills, California.
Pract Radiat Oncol
March 2014
Department of Radiation Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, California.
Purpose: The 6-MV flattening filter-free mode (6F) of the Varian TrueBeam (Varian Medical Systems, Palo Alto, CA) enables faster dose delivery and shortens treatment time, which are especially beneficial for stereotactic radiosurgery. This study is to evaluate the feasibility and advantages of using 6F in stereotactic radiosurgery treatment of multiple brain lesions in comparison with regular 6-MV mode (6X).
Materials And Methods: Ten patients having 2-12 brain metastases treated by intensity modulated stereotactic radiosurgery were selected for this study.
Arch Pathol Lab Med
July 2011
Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA.
Context: The number of paraffin blocks submitted for patients enrolled in clinical research trials appears to be declining.
Objective: To obtain information on laboratory policies and procedures in complying with requests to submit paraffin blocks for research.
Design: A questionnaire was sent to members of a voluntary market research panel composed of pathologists representing a broad spectrum of experience and practice settings.
Arch Pathol Lab Med
June 2010
Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA.
Context: Estrogen receptor and progesterone receptor status is assessed on all newly diagnosed, invasive breast carcinomas and in recurrences to determine patient eligibility for hormonal therapy, but 10% to 20% of estrogen receptor and progesterone receptor test results are discordant when tested in multiple laboratories.
Objective: To define the analytic (technical) validation requirements for estrogen receptor and progesterone receptor immunohistochemistry assays used to select patients for hormonal therapy.
Data Sources: Literature review and expert consensus.
Arch Pathol Lab Med
October 2006
Department of Pathology, St Jude Medical Center, Fullerton, Calif, USA.
Context: Correct assessment of human epidermal growth factor receptor 2 (HER2) status is essential in managing patients with invasive breast carcinoma, but few data are available on the accuracy of laboratories performing HER2 testing by immunohistochemistry (IHC).
Objective: To review the results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.
Design: The HER2 survey is designed for laboratories performing immunohistochemical staining and interpretation for HER2.
Tex Heart Inst J
January 2004
Department of Cardiovascular and Thoracic Surgery, St. Jude Medical Center, Fullerton, California 92835, USA.
Aneurysms of the sinuses of Valsalva, when detected before rupture, are repaired electively. When they are small, they are most frequently repaired by direct closure; when they are large, they are repaired with a prosthetic patch. When they are associated with prolapse of the corresponding aortic cusp and aortic insufficiency, valve replacement is usually performed concomitantly.
View Article and Find Full Text PDFTex Heart Inst J
February 2003
The Department of Cardiovascular Surgery, St Jude Medical Center, Fullerton, California 92835, USA.
Tex Heart Inst J
September 2001
Department of Cardiovascular Surgery, St Jude Medical Center, Fullerton, California 92835, USA.
To date, venous reconstruction has not been as successful as arterial reconstruction. Prosthetic materials used as venous substitutes produce much lower patency rates with a higher incidence of early thrombosis than those used as arterial substitutes. We describe the case of a 38-year-old obese woman in whom we encountered an unexpected tear of the common iliac vein intraoperatively, during an anterior approach to the lumbar spine.
View Article and Find Full Text PDFAnn Thorac Surg
March 2001
Department of Cardiothroacic Surgery, St. Jude Medical Center, Fullerton, California, USA.
Saccular aneurysms of the aortic arch are usually managed with patch graft aortoplasty or with tube graft replacement. In either case, hypothermic circulatory arrest is necessary. The use of stapling devices has revolutionized pulmonary and gastrointestinal surgery; however, these instruments have rarely been used in aortic surgery except during thromboexclusion procedures.
View Article and Find Full Text PDFEmerg Med Serv
November 2000
St. Jude Medical Center in Fullerton, CA, USA.